GL1X · GenesisL1 explorer

MolNFT v1 · #21686 · protein

Refined crystal structures of subtilisin novo in complex with wild- type and two mutant eglins. comparison with other serine proteinase inhibitor complexes

1SIB · Subtilisin novo bpn': “Refined crystal structures of subtilisin novo in complex with wild- type and two mutant eglins. comparison…”. X-ray diffraction, 1 ligand (CA), 1 pocket (best druggability 0.62). MolNFT v1 #21686 on GenesisL1…

PDB
1SIB
Type
protein
Length
338 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Subtilisin novo bpn'; Eglin C
EC
3.4.21.62
UniProt
P00782, P01051
Ligands
CA
Pockets
1 · best druggability 0.62

Structure

x-ray diffraction · 2 distinct chains · 25% helix, 23% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ESubtilisin novo bpn' (EC 3.4.21.62)protein27527% helix, 21% strandP00782
IEglin Cprotein6317% helix, 33% strandP01051

Ligands and binding sites

  • CA · Calcium ion · metal · 2 copies · chains E

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12270.620.8237empty

Interfaces

1 interface between chains.

  • E–I · 770 Ų buried · 16 hydrogen bonds · protein-protein

Compared structures

  • 1SIB · Refined crystal structures of subtilisin novo in complex with wild-type and two mutant… · the same entry in another collection · chain E against E, TM-score 1.00
  • P00782 · AlphaFold monomer V2.0 prediction for subtilisin bpn' (P00782) · a predicted model of the same protein · chain E against A, TM-score 1.00
  • P01051 · AlphaFold monomer V2.0 prediction for eglin C (P01051) · a predicted model of the same protein · chain I against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.